Does a bioresorbable scaffold reduce target-vessel failure compared to a metallic stent in patients undergoing routine PCI?
In routine PCI, bioresorbable scaffolds do not improve target-vessel failure rates compared to metallic stents and are associated with an increased risk of device thrombosis at 2 years.
In this preliminary report of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-vessel failure between the patients who received a bioresorbable scaffold and the patients who received a metallic stent. The bioresorbable scaffold was associated with a higher incidence of device thrombosis than the metallic stent through 2 years of follow-up. (Funded by Abbott Vascular; AIDA ClinicalTrials.gov number, NCT01858077 .).
Wykrzykowska et al. (Wed,) studied this question.